The value of opportunistic chlamydia screening is called into question in this week’s BMJ. Dr Nicola Low, an epidemiologist at the University of Berne in Switzerland argues that claims about screening are not supported by rigorous research or practice. And she shows how uncritical acceptance of the effectiveness of chlamydia screening in Sweden and the United States led to the funding of the National Chlamydia Screening Programme in England, before the balance of benefits and harms was understood.>>> Discuss This Story
